Correct. There's a lengthy waiting list of articles waiting for publication in the most respected journals: waiting for peers to be available to conduct the review, then waiting while the peers conduct the review, then waiting in the queue for publication. Really big news can often be summarised earlier in "letters".
In my view, this constraint — "The final results of the study will not be available to Neurotech or the public until the investigation has been published" (italics and underscore are mine) — raises questions over the timing of the FDA application:
1) Can the FDA application be submitted without the trial results? Surely not... otherwise why are we conducting the trial?
2) Can the trial results be submitted directly to the FDA independently by the operators without disclosure to Neurotech? Again, surely not because until the work is reviewed it has no credibility.
I suspect that this is why the market has offloaded NTI... investors have realised they have a wait of up to 6 months before further action is likely. They'll be looking for opportunities in the interim.
NTI Price at posting:
22.5¢ Sentiment: Hold Disclosure: Held
